Clinical trials: sponsored by AstraZeneca
Non-Small Cell Lung Cancer
Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)
This study was designed to evaluate the safety and efficacy of trastuzumab deruxtecan in HER2-mutated metastatic non-small cell lung cancer (NSCLC) participants who had disease recurrence or progression during/after at least one…
- Trial name
- DESTINY-LUNG02 (NCT04644237)
- Testing
- Trastuzumab deruxtecan
- Where
- 50 sites in United States, Australia and 8 more
- Volunteers
- 152 people
- Sponsor
- Daiichi Sankyo
Small Cell Lung Cancer
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy
This is a Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with LS-SCLC Who Have Not Progressed…
- Trial name
- ADRIATIC (NCT03703297)
- Testing
- Durvalumab, Tremelimumab
- Where
- 183 sites in United States, Argentina and 17 more
- Volunteers
- 730 people
- Sponsor
- AstraZeneca
Bladder Cancer
Assessement of the Concordance of Genomic Alterations Between Urine and Tissue in High-Risk NMIBC Patients
The analysis of cell-free tumor DNA (cfDNA) in plasma has emerged as a clinically relevant predictive and prognostic biomarker in several metastatic solid malignancies, and even now represents standard-of-care for prescription of…
- Trial name
- ALU (NCT04412070)
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Hopital Foch
Non Small Cell Lung Cancer
Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC
This is a Phase I, open-label, 2-part study in patients with a confirmed diagnosis of epidermal growth factor receptor (EGFR) mutation positive (EGFRm+) non-small cell lung cancer (NSCLC), who have progressed following prior…
- Trial name
- NCT02197234
- Testing
- Pharmacokinetic sampling - AZD9291, Simvastatin, AZD9291 tablet dosing
- Where
- 16 sites in United States, Belgium and 3 more
- Volunteers
- 52 people
- Sponsor
- AstraZeneca
Asthma, Asthma in Children
Diagnostic and Translational Values of Point-of-care Blood Eosinophils and Exhaled Nitric Oxide (FeNO) in People Referred by Primary Care for Suspected Asthma
Asthma is characterised by episodic symptoms (attacks) caused by airway inflammation and decreased airflow to the lungs. It affects 10% of the Canadian population and is the most common chronic disease in childhood.
- Conditions
- Asthma, Asthma in Children, Diagnosis, Inflammation
- Trial name
- DIVE (NCT05992519)
- Testing
- ¸FeNO
- Where
- Canada
- Volunteers
- 123 people
- Sponsor
- Université de Sherbrooke
Advanced Non Small Cell Lung Cancer, Advanced (Inoperable) Non Small Cell Lung Cancer
Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)
This is a 2 part study in patients with EGFRm+ non small cell lung cancer (NSCLC), whose disease has progressed on an EGFRm TKI, who are refractory or resistant to standard therapy.
- Trial name
- NCT02157883
- Testing
- Pharmacokinetic sampling, AZD9291, Itraconazole
- Where
- 16 sites in United States, Belgium and 4 more
- Volunteers
- 39 people
- Sponsor
- AstraZeneca
Coronary Artery Disease
DIAMOND - Dual Antiplatelet Therapy to Reduce Myocardial Injury
Heart attacks are most commonly caused by rupture of fatty deposits (plaques) within the wall of heart blood vessels. It appears that this process can also frequently occur without causing any symptoms and these events likely…
- Trial name
- DIAMOND (NCT02110303)
- Testing
- Ticagrelor
- Where
- United Kingdom
- Volunteers
- 220 people
- Sponsor
- University of Edinburgh
Breast Cancer, Non-small Cell Lung Carcinoma
DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer
This two-part study will include a dose escalation part to determine the recommended dose for expansion of DS8201a and pembrolizumab and a dose expansion part to evaluate efficacy, safety, and tolerability of the combination.
- Trial name
- NCT04042701
- Testing
- Trastuzumab deruxtecan (DS-8201a), Pembrolizumab
- Where
- 30 sites in United States, France and 2 more
- Volunteers
- 115 people
- Sponsor
- Daiichi Sankyo
Dyslipidemia
A Study to Assess the Efficacy, Safety and Tolerability of Different Doses of AZD0780 in Patients With Dyslipidemia
The primary purpose of this study is to measure the effect of different daily doses of AZD0780 on Low-Density Lipoprotein (LDL-C) levels compared with placebo in participants with dyslipidemia.
- Trial name
- PURSUIT (NCT06173570)
- Testing
- AZD0780
- Where
- 55 sites in United States, Canada and 6 more
- Volunteers
- 428 people
- Sponsor
- AstraZeneca
Healthy Participants
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled AZD4604 in Healthy Japanese and Chinese Participants.
The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics (PK) of AZD4604 when administered as single or multiple inhaled doses to healthy Japanese and Chinese participants.
- Trial name
- NCT06519968
- Testing
- AZD4604
- Where
- United Kingdom
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Lung Cancer, Biliary Tract Cancer
Open Label, Multicenter, Real World Practice of Durvalumab (Imfinzi PMS)
The objectives of this study are to assess safety and efficacy of Imfinzi (durvalumab) in a real world setting in patients treated with Imfinzi under the approved indication in Korea.
- Trial name
- Imfinzi PMS (NCT04068168)
- Where
- 24 sites in South Korea
- Volunteers
- 712 people
- Sponsor
- AstraZeneca
Asthma, Osteoporosis, Osteopenia
Long-term Effect of Steroid on Metabolic Diseases in Asthmatics
The goal of this retrospective/observational study is to compare the clinical outcomes between the high-cumulative-dose group and the low- cumulative-dose group of oral/inhaled corticosteroid in the long-term management of asthma…
- Conditions
- Asthma, Osteoporosis, Osteopenia, Osteoporosis Risk, Osteoporotic Fractures
- Trial name
- NCT06279078
- Testing
- Corticosteroid
- Where
- South Korea
- Volunteers
- 19,968 people
- Sponsor
- Ajou University School of Medicine
Mantle Cell Lymphoma
A Disease Registry of Patients With Mantle Cell Lymphoma
The purpose of this study is to create a patient registry in order to assess treatment patterns, physician reported clinical outcomes and patient-reported health-related quality of life among patients diagnosed with Mantle Cell…
- Trial name
- SUMMIT (NCT03816683)
- Where
- 32 sites in United States
- Volunteers
- 227 people
- Sponsor
- AstraZeneca
Asthma
Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA
This is a Phase 2a, multicentre, randomised, placebo-controlled, double-blind, parallel-group study to evaluate the efficacy, safety and PK of AZD4604 administered BID using a dry-powder inhaler at one dose level over a 12-week…
- Trial name
- AJAX (NCT06020014)
- Testing
- AZD4604
- Where
- 124 sites in United States, Argentina and 16 more
- Volunteers
- 339 people
- Sponsor
- AstraZeneca
Healthy Participants
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AZD5148 in Healthy Adults
The purpose of this study is to measure safety, tolerability, and pharmacokinetics (PK) of a single dose of AZD5148 administered via intravenous (IV) bolus or intramuscular (IM) injection in healthy participants
- Trial name
- NCT06469151
- Testing
- AZD5148
- Where
- 4 sites in United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Dyslipidemia
A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C.
The main aim of this study is to assess the effects of AZD0780 when added on top of ezetimibe or ezetimibe and rosuvastatin or ezetimibe and bempedoic acid.
- Trial name
- NCT06742853
- Testing
- AZD0780, Ezetimibe, Rosuvastatin
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Non-small Cell Lung Cancer (NSCLC)
Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC
This study evaluates the combination of two well-tolerated therapies, osimertinib and Stereotactic Ablative Radiation (SABR).
- Trial name
- NCT03667820
- Testing
- Osimertinib, SABR
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- University of Texas Southwestern Medical Center
Major Bleeding
A Study to Describe the Characteristics, Health Care Interventions and Outcomes of Patients With Major Bleedings in the Presence of Factor Xa Inhibitor Treatment
REVERXaL study aims to increase the understanding of the patient characteristics, bleeding presentation, health care interventions provided, and the clinical as well as self-reported health outcomes of patients with major…
- Trial name
- REVERXaL (NCT06147830)
- Testing
- None (Observational study)
- Where
- 75 sites in United States, Germany and 2 more
- Volunteers
- 2,202 people
- Sponsor
- AstraZeneca
Renal Impairment
Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD6234
This study will evaluate the pharmacokinetics (PK), safety, and tolerability of single subcutaneous dose of AZD6234 with end stage renal disease, severe, and possibly moderate and mild renal impairment in comparison to a matched…
- Trial name
- NCT06845813
- Testing
- AZD6234
- Where
- 3 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus (T2DM)
Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DM
Study D1690L00149 is a 24-week, multicentre, randomized, parallel, interventional, non-inferiority, open-label study designed to compare the FDC Regimen of Dapagliflozin/Metformin XR with the Dapagliflozin co-administered with…
- Trial name
- NCT06327815
- Testing
- Xigduo (Dapagliflozin and Metformin hydrochloride extended-release) tablets, Dapagliflozin tablets and Metformin HCl extended-release tablets
- Where
- 35 sites in China
- Volunteers
- 633 people
- Sponsor
- AstraZeneca